No significant difference in DRFI was observed for patients with either hormone receptor-positive (adjusted HR = 0.94, 95% CI 0.60–1.48; Fig. 2c) or negative (adjusted HR = 0.92, 95% CI 0.43–1.95; Fig. 3c) breast cancer (Pinteraction = 0.95; Supplementary Table 6). Here, NR4A1 is linked to breast cancer.